Shortening Omalizumab Treatment for Severe Asthma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the feasibility of discontinuing Omalizumab (OMA) treatment in patients with well-controlled severe allergic asthma after at least 33 months of therapy. The research aims to determine if patients can maintain acceptable asthma control after stopping OMA, which is known to reduce severe exacerbations and improve asthma management. By assessing asthma control post-discontinuation, the study seeks to provide insights into the optimal duration of OMA therapy and its impact on patient quality of life and healthcare costs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patient \>18 years old
* Treated with OMA, prescribed by a pulmonologist , for at least 33 months for severe allergic asthma
* Well controlled with the treatment (ACT score ⩾ 18) and having experienced no more than one exacerbation in the year preceding inclusion. An exacerbation is defined as an oral or injectable steroid course for at least 2 days and/or a minimum doubling of the usual steroid dose for at least 2 days for steroid dependent patients

Exclusion Criteria:

* Patient refusing to stop OMA treatment, whatever the reason
* Patient with other reason other than good asthma control to stop OMA, such as a side effect, planned or ongoing pregnancy, or planned switch to another step 5 asthma treatment (mepolizumab, benralizumab, dupilumab, reslizumab, daily oral steroids, bronchial thermoplasty, …)
* Patient not covered by Health Insurance
* Patient under curatorship, guardianship or safeguarding of justice
* Patient whose adherence to asthma treatments is considered poor or questionable by the investigator
* Patient participating in another intervention research
* Pregnant or lactating patient
* Patient refusing to sign consent

Where it's running

• Hôpital Bichat-Claude Bernard
  Paris, Île-de-France Region, France Recruiting

Study contacts

• Principal investigator: Camille TAILLE, Professor — Assistance Publique - Hôpitaux de Paris
• Study coordinator: Camille TAILLE, Professor
• Email: camille.taille@aphp.fr
• Phone: 01 40 25 68 63

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Chronic Respiratory Disease Participant Engagement

  This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.

  Recruiting Richmond Pharmacology Limited · London · NCT07924462

• HB0056 in adults with moderate to severe asthma

  This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.

  Recruiting at 2 sites Phase 1/2 Shanghai Huaota Biopharmaceutical Co., Ltd. · Beijing and 1 other locations · NCT07899996

• Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations

  This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.

  Recruiting at 4 sites Phase 3 Pfizer · River Forest, Illinois and 11 other locations · NCT07869043

• Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma

  This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.

  Recruiting Phase 1 Chiesi Farmaceutici S.p.A. · Leeds and 2 other locations · NCT07851623

• Oral Food Challenge After Starting Omalizumab in Food Allergy

  This trial tests whether omalizumab begins to help with food allergy within 2 to 4 weeks after starting treatment in people with a confirmed food allergy.

  Recruiting Phase 4 Johns Hopkins University · Baltimore, Maryland · NCT07845552

• Severe chronic urticaria not responding to high-dose omalizumab in France

  This study looks at adults with chronic spontaneous or inducible urticaria who don’t respond to optimized omalizumab to see what factors are linked to non-response and what other options people use.

  Recruiting Centre Hospitalier Universitaire de Besancon · Besançon, Franche-comté · NCT07833696

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.